Medication Taking and Diabetes

Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2005. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2005.

Mason BJ , Matsuyama JR , Jue SG Assessment of sulfonylurea adherence and metabolic control. Diabetes Educ. 1995;21:52-57.

Matsuyama JR , Mason BJ , Jue SG Pharmacists' interventions using electronic medication event monitoring device's adherence data versus pill counts. Ann Pharmacother. 1993;27:851-855.

Paes AH , Bakker A. , Soe-Agne CJ. Impact of dosage frequency on patient compliance. Diabetes Care. 1997;20(10):1512-1517.

Rosen MI , Beauvais JE , Rigsby MO , Salahi JT , Ryan CE , Cramer JA Neuropsychological correlates of sub-optimal adherence to metformin . J Behav Med. 2003;26:349-360.

Rosen MI , Rigsby MO , Salahi JT , Ryan CE , Cramer JA , Inzucchi S. Electronic monitoring and counseling to improve medication adherence . Behav Res Ther. 2004;42:409-422.

Ciechanowski PS , Katon WJ , Russo JE Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Intern Med. 2000;160:3278-3285.

Melikian C. , White J. , Vanderplas A. , et al. Adherence to oral antidiabetic therapy in managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther. 2002;24:460-467.

Sclar DA , Robison LM , Skaer TL , Dickson WM , Kozma CM , Reeder CE Sulfonylurea pharmacotherapy regimen compliance in a Medicaid population: influence of age, gender, and race. Diabetes Educ. 1999;25(4):531-538.

Donnan PT , MacDonald TM , Morris AD ; for the DARTS/MEMO Collaboration. Adherence to prescribed oral hypoglycemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med. 2002;19:279-282.

Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes . Diabetes Educ. 2006;32(1):9S-18S.

Siminerio L. Challenges and strategies for moving patients to injectable medications. Diabetes Educ. 2006;32(suppl 2):82S-90S.

Polonsky WH , Fisher L. , Guzman S. , Villa-Caballero L. , Edelman SV Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem . Diabetes Care. 2005;28(1):2543-2546.

Morris AD , Boyle Dir , McMahon AD , Greene SA , MacDonald TM , Newton RW ; for the DARTS/MEMO Collaboration. Adherence to insulin treatment, glycemic control, and ketoacidosis in insulin-dependent diabetes mellitus. Lancet. 1997;350: 1505-1510.

Gerber RA , Cappelleri JC , Kourides IA , Gelfand RA Treatment satisfaction with inhaled insulin in patient with type 1 diabetes: a randomized controlled trial. Diabetes Care. 2001;24:1556-1559.

Nathan DM , Buse JB , Davidson MB , et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2006;29(8):1963 -1972.

Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.

Turner RC , Cull CA , Frighi V. , Holman RR Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005-2012.

UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.

UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet . 1998;352: 854-865.

Stratton IM , Adler AI , Neil Haw , et al. Association of glycaemia with macrovascular and microvascular complications in type 2 diabetes (UKPDS 35): prospective observational study. BMJ . 2000;321:405-412.

American Association of Clinical Endocrinologists. State of Diabetes in America. http://www.aace.com/public/awareness/stateofdiabetes/DiabetesAmericaReport.pdf Accessed May 20, 2006.

Koro CE , Bolin SJ , Bourgeouis N. , Fedder DO Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27(1):17-20.

Saaddine JB , Cadwell B. , Gregg EW , et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002 . Ann Intern Med. 2006;144(7):465-474.

Ary DV , Toobert D. , Wilson W. , Glasgow RE Patient perspective on factors contributing to noncompliance to diabetes regimen . Diabetes Care. 1986;9(2):168-172.

Introduction. Diabetes Care. 2007;30:S1-S2.

Boccuzzi SJ , Wogen J. , Fox J. , et al. Utilization of oral hypoglycemic agents in a drug-insured U.S. population. Diabetes Care. 2001;24(8):1411-1415.

Vanderpoel DR , Hussein MA , Watson-Heidari T. , et al. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis . Clin Ther. 2004;26:2066-2075.

Hertz RP , Unger AN , Lustik MB Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer sponsored health insurance. Clin Ther. 2005;27(7): 1064-1073.

Schectman JM , Nadkarni MM , Voss JD The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care. 2002;25:1015-1021.

Catalan VS , Couture JA , LeLorier J. Predictors of persistence if use of the novel antidiabetic agent acarbose . Arch Intern Med. 2001;161:1106-1112.

Evans JM , Donnan PT , Morris AD Adherence to oral hypoglycemic agents prior to insulin therapy in type 2 diabetes . Diabet Med. 2002;19:685-688.

Venturini F. , Nichol MB , Sung JC , et al. Compliance with sulfonylureas in a health maintenance organization: a pharmacy record-based study. Ann Pharmacother. 1999;33:281-288.

Spoelstra JA , Stolk RP , Heerdink ER , et al. Refill compliance in type 2 diabetes mellitus: a predictor of switching to insulin therapy. Pharmacoepidemiol Drug Saf. 2003;12:121-127.

Dezii CM , Kawabata H. , Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J. 2002;95(1):68-71.

Morningstar BA , Sketris IS , Kephart GC , Sclar DA Variation on pharmacy prescription refill adherence measures by type of oral antihyperglycemic drug therapy in seniors in Nova Scotia, Canada. J Clin Pharm Ther. 2002;27:213-220.

Rhee MK , Slocum W. , Ziemer DC , et al. Patient adherence improves glycemic control. Diabetes Educ. 2005;31(2):240-250.

Doro P. , Benko R. , Kosik E. , et al. Utilization of oral antihyperglycemic drugs over a 7-year period (1998-2004) in a Hungarian population and adherence to drug therapy. Eur J Clin Pharmacol. 2005;61:893-897.

Balkrishnan R. , Rajagopalan R. , Shenolikar RA , et al. Healthcare costs and prescription adherence with introduction of thiazolidinedione therapy in Medicaid type 2 diabetes patients: a retrospective data analysis. Curr Med Res Opin. 2004;20(10): 1633-1640.

Dailey G. , Kim MS , Lian JF Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a Medicaid patient population with type 2 diabetes mellitus. Clin Ther. 2001;23(8):1311-1320.

Brown JB , Nichols GA , Glauber HS , et al. Ten-year follow-up of antidiabetic drug use, nonadherence, and mortality in a defined population with type 2 diabetes mellitus. Clin Ther. 1999;21(6): 1045-1057.

Morris AD , Boyle DI , McMahon AD , et al. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. Lancet. 1997;350:1505-1510.

Krapek K. , King K. , Warren SS , et al. Medication adherence and associated hemoglobin A1C in type 2 diabetes. Ann Pharmacother. 2004;38:1357-1362.

Kalsekar ID , Madhaven SS , Amonkar MM , et al. Depression in patients with type 2 diabetes: impact on adherence to oral hypoglycemic agents . Ann Pharmacother. 2006;40:605-611.

Kardas P. The DIACOM study (effect of DosIng frequency of oral Antidiabetes agents on the COMpliance and biochemical control of type 2 diabetes). Diabetes Obes Metab. 2005;7:722-728.

Charpentier G. , Fleury F. , Dubroca I. , et al. Electronic pill-boxes in the evaluation of oral hypoglycemic agent compliance. Diabetes Metab. 2005:31;189-195.

Grant RW , Devita ND , Singer DE , Meigs JB Polypharmacy and medication adherence in patients with type 2 diabetes . Diabetes Care. 2003;26(5):1408-1412.

Lawson ML , Cohen N. , Richardson C. , et al. A randomized trial of regular standardized telephone contact by a diabetes nurse educator in adolescents with poor diabetes control. Pediatr Diabetes. 2005;6:32-40.

Mendez FJ , Belendez M. Effects of a behavioral intervention on treatment adherence and stress management in adolescents with IDDM. Diabetes Care. 1997 ;20(9):1370-1375.

Ellis DA , Frey MA , Naar-King S. , et al. Use of multisystemic therapy to improve regimen adherence among adolescents with type 1 diabetes in chronic poor metabolic control. Diabetes Care. 2005;28(7):1604-1610.

Skaer TL , Sclar DA , Markowski DJ , Won KH Effect of value-added utilities on prescription refill compliance and Medicaid health care expenditures—a study of patients with non-insulin-dependent diabetes mellitus. J Clin Pharm Ther. 1993 ;18:295-299.

Grant RW , Devita NG , Singer DE , Meigs JB Improving adherence and reducing medication discrepancies in patients with diabetes. Ann Pharmacother. 2003;37:962-969.

Littenberg B. , MacLean CD, Hurowitz L. The use of adherence aids by adults with diabetes: a cross-sectional survey. BMC Fam Pract. 2006;7:1-5.

Rubin RR Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus . Am J Med. 2005;118(5A):27S-34S.

Kilbourne AM , Reynold CF , Good CB , Sereika SM , Justice AC , Fine MJ How does depression influence diabetes medication adherence in older patients? Am J Geriatr Psychiatry. 2005;13(3): 202-210.

Lin EHB , Oliver M. , Katon W. , et al. Relationship of depression and diabetes self-care, medication adherence, and preventive care. Diabetes Care. 2004;27:2154-2160.

Ziemer DC , Doyle JP , Barnes CS , et al. An intervention to overcome clinical inertia and improve diabetes mellitus control in a primary care setting. Arch Intern Med. 2006;166:507-513.

Grant R. , Adams AL , Trinacty CM , et al. Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management. Diabetes Care. 2007;30(4):807-812.

Pladevall M. , Divine G. , Williams LK , Xi H. , Potts LA , Lafata JE Clinical outcomes and adherence to medications measured by claims data in patients with diabetes . Diabetes Care. 2004;27:2800-2805.

Hepke KL , Martus MT , Share DA Costs and utilization associated with pharmaceutical adherence in a diabetic population. Am J Manag Care. 2004 ;10(pt 2):144-151.

Maier C. , Mustapic D. , Schustert E. , Luger A. , Eher R. Effect of a pocket-size tablet-dispensing device on glycaemic control in type 2 diabetic patients. Diabet Med. 2006;23:40-45.

Ho PM , Rumsfeld JS , Masoudi FA , et al. Effect of medication nonadherence on hospitalizations and mortality among patients with diabetes mellitus. Arch Intern Med. 2006:166:1836-1841.

Chao J. , Nau DP , Aikens JE , Taylor SD The mediating role of health beliefs in the relationship between depressive symptoms and medication adherence in persons with diabetes. Res Social Adm Pharm. 2005;1(4):508-525.

Farmer A. , Kinmonth AL , Sutton S. Measuring beliefs about taking hypoglycemic medication among people with type 2 diabetes. Diabet Med. 2006;23:265-270.

Walker EA , Moltich M. , Kramer MK , et al; for the Diabetes Prevention Program Research Group. Adherence to preventive medications: predictors and outcomes in the diabetes prevention program. Diabetes Care . 2006;29(9):1997 -2002.